Key result
In a meta-analysis of 49 RCTs comprising 4,610 patients, Wenxin keli demonstrated better clinical efficacy for arrhythmia, angina, and heart failure compared to other available treatments.
Why the study?
Does Wenxin keli improve clinical efficacy compared to other available treatments in patients with cardiovascular diseases?
Meta-Analysis (n=4,610)
Does Wenxin keli improve clinical efficacy compared to other available treatments in patients with cardiovascular diseases?
Wenxin keli may offer clinical benefits for arrhythmia, angina, and heart failure, though high-quality evidence is currently lacking.
Answers are grounded in this paper and cite their sources.
May support adjunctive Wenxin Keli for arrhythmia, angina, and heart failure; leaves open need for rigorous multicenter RCTs.
OBJECTIVE: The aim of the study was to evaluate the effectiveness, safety, and cost associated with Wenxin keli in the treatment of cardiovascular diseases based on meta-analysis. METHODS: The terms "Wenxin keli" and "Wenxin" were used as the search terms in the PubMed, ProQuest, Springer, the Cochrane Library, CNKI (China National Knowledge Infrastructure), VIP (Chinese Scientific Journals Database), and Wan fang electronic databases (from January 2000 to October 2015). Relevant print journals and conference papers were also searched. Studies on randomized controlled trials (RCTs) of Wenxin keli used in the treatment of cardiovascular diseases were screened, and its indications were classified. Meta-analysis of these studies was conducted using the RevMan 5.2 software. RESULTS: A total of 49 RCTs (n=4,610) were included, 29 of which focused on arrhythmia, seven on angina, seven on heart failure, two on viral myocarditis, and four on menopausal syndrome. Analysis of the therapeutic indications of Wenxin keli showed that it was comparatively more curative and effective than other available treatments for cardiovascular diseases. CONCLUSION: Wenxin keli showed better clinical efficacy in the treatment of arrhythmia, angina, and heart failure; however, more high-quality evidence is needed to support its use in the clinical setting.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2016) conducted a meta-analysis in cardiovascular diseases (n=4,610). Wenxin keli vs. other available treatments was evaluated on clinical efficacy. In a meta-analysis of 49 RCTs comprising 4,610 patients, Wenxin keli demonstrated better clinical efficacy for arrhythmia, angina, and heart failure compared to other available treatments.
Synapse has enriched 10 related papers. Consider them for comparative context: